Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
This presentation will delve into the complexities of sustaining the global HIV commitment amidst evolving health priorities and funding landscapes. This session will explore the opportunities and risks of integrating HIV care and prevention into broader health services. From innovative service delivery models to community-driven solutions, we will highlight how integration can enhance health system…
Humanized mouse models, immunodeficient mice transplanted with human cells/tissues, have been used by HIV researchers for over 30 years to study aspects of HIV infection (e.g. transmission, pathogenesis, and persistence) and to perform efficacy testing of novel prevention, treatment, and cure approaches. This presentation will introduce the most commonly used humanized mouse models for HIV…
Over the past 25 years, the global HIV response has made remarkable progress at controlling HIV epidemics, including reducing new infections and ensuring healthy lives for people living with HIV. However, progress has not been equal across epidemic settings or populations affected by HIV, and overall remains off track to achieve targeted 90% reductions in new infections…
Hepatitis B remains a significant cause of liver disease and remains the leading cause of hepatocellular carcinoma worldwide. Effective therapy for hepatitis B is available, and nucleos(t)ide analogs (NAs) suppress hepatitis B DNA levels and normalize ALT levels. Long-term treatment can lead to reduction in necroinflammatory activity, with potential improvement in fibrosis or reduction in…
Current ART has the capacity to drastically suppress but not abolish previously infected cells which can persist for the life of the host. This persistent rebound competent virus is the primary barrier to HIV cure. This long-term stable virus resides in multiple subsets of CD4+ T cells, particularly CD4+ memory T cells, and possibly macrophages…
This session explores the transformative impact of artificial intelligence (AI) across the HIV research continuum, from basic science to public health. Key highlights include AI’s role in accelerating drug discovery, optimizing clinical trials, and enhancing HIV care and prevention strategies. Emphasis is placed on ethical considerations, community engagement, and implementation science to ensure equitable and…
Recent research underscored that HIV transcription remains a critical step in the viral life cycle. Especially the transition between active and latent infection is critically regulated by viral factors such as Tat and many host factors that either control the transcriptional activity of the virus directly or the epigenetic landscape around it. It has become…
Since 1990 an estimated 11 million children have been born with HIV and with the successful global role out of paediatric antiretroviral therapy (ART) increasing numbers of young people are transitioning through adolescence and entering adult care. In resourced settings with earlier access to ART the oldest survivors are now entering their 5th decade of…
Menopause represents a highly vulnerable time for women physically, mentally, and socially. The growing body of menopause research among women living with HIV (WLWH) demonstrates that this vulnerable population experiences greater mood and vasomotor symptom burden, which adversely impacts adherence to clinic visits and antiretroviral therapy. Estrogen loss associated with menopause may further enhance the…
Children aged 0-15 years lag behind adults in achieving HIV treatment goals across HIV testing, initiation of antiretroviral therapy and viral suppression. While early diagnosis of pediatric HIV has scaled up significantly, children continue to slip through the cracks and remain undiagnosed and untreated. For children living with HIV, challenges in adherence to treatment is…